Is Egrifta (Tesamorelin) Legal in Minnesota?

HealthRX.com

Yes, tesamorelin is legal by prescription in Minnesota

1.28 mgDaily dose of Egrifta WR, the other labeled formulationSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 1.4 mgDaily dose of Egrifta SV, one of the two labeled formulationsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.28 mgDaily dose of Egrifta WR, the other labeled formulationSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 11.6 mgVial size of Egrifta WR, which is dosed at 1.28 mg once dailySource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • Federal status / FDA-approved prescription drug, approved November 10, 2010 (BLA 022505) [1]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
  • Labeled formulations / Egrifta SV 1.4 mg daily and Egrifta WR 1.28 mg daily; not substitutable [2][3]
  • Weight loss / Not indicated; the label describes a weight-neutral effect [2]
  • Compounding / No FDA category for tesamorelin on its bulk-substance or safety-risk lists [4][5][6]
  • Sport / Prohibited at all times under WADA S2.2.4 [7]

What federal law says about Egrifta

The FDA approved tesamorelin as Egrifta on November 10, 2010 under application BLA 022505 [1]. The approved use is narrow: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label also says there are no data showing it improves adherence to antiretroviral therapy [2].

Which formulations do the labels describe?

The current labels describe two formulations with different doses, and the labels state they are not substitutable [2][3]. Egrifta SV is a 2 mg vial dosed at 1.4 mg once daily by subcutaneous injection into the abdomen [2]. Egrifta WR is an 11.6 mg vial dosed at 1.28 mg once daily [3]. Both labels are dated July 29, 2026 [2][3].

Does Minnesota have its own tesamorelin rule?

Minnesota's controlled-substance schedules are set out in Minn. Stat. § 152.02 [8]. The Minnesota Board of Pharmacy home page covers licensing and online license verification for pharmacies and pharmacists [9], and the Board of Medical Practice home page covers licensing and license verification for physicians and other practitioners [10]. Neither page mentions tesamorelin or sets out a tesamorelin-specific restriction.

Questions worth asking

Choose the questions you want to keep

Is compounded tesamorelin legal in Minnesota?

FDA has not placed tesamorelin in a category on its bulk-substance lists or on its significant-safety-risk list [4][5][6]. That does not establish whether a particular compounded tesamorelin product is legal in Minnesota. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [11]. Tesamorelin is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [12][13].

Is tesamorelin legal in sport?

Not under anti-doping rules. WADA names tesamorelin in S2.2.4 among growth hormone releasing factors and prohibits it at all times, in and out of competition [7]. It appears on both the 2026 and the 2027 Prohibited Lists [7][14].

Is Egrifta (tesamorelin) legal in Minnesota?
Yes, by prescription. It is an FDA-approved prescription drug (BLA 022505, approved November 10, 2010) for reducing excess abdominal fat in HIV-infected adults with lipodystrophy [1][2].
Is compounded tesamorelin legal in Minnesota?
That is a separate question from Egrifta's approval. FDA has not placed tesamorelin in a category on its bulk-substance lists or on its significant-safety-risk list [4][5][6], which does not establish whether a particular compounded tesamorelin product is legal in Minnesota. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [11].
What is Egrifta approved to treat?
Only the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label states it is not indicated for weight loss because it has a weight-neutral effect, and that long-term cardiovascular safety has not been established [2].
Is the dose 2 mg daily?
The 2 mg daily dose came from trials of the original 1 mg/vial product. The current labels describe Egrifta SV at 1.4 mg daily and Egrifta WR at 1.28 mg daily [2][3].
Show all 14 referencesHide references
Evidence overview for Is Egrifta (Tesamorelin) Legal in Minnesota?